A Phase 3 interventional study of Oxaliplatin 130 mg/m^2 and Capecitabine 1000 mg/m^2 in Colorectal Cancer, sponsored by Hoffmann-La Roche. Completed at 236 sites in 33 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-10-06.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 206 studies testing oxaliplatin in Colorectal Neoplasms — 21 open to participants now, 25 under way, 6 of them phase 3. Oxaliplatin · Colorectal Neoplasms.
Among the 206 studies testing oxaliplatin in Colorectal Neoplasms, this one is the 4th largest by enrollment of the 183 interventional ones that give a count, is one of 13 that started in 2003, is one of 36 in phase 3, and was the 35th registered.
6,554 studies on the registry are indexed under Colorectal Neoplasms; 1,665 are open to participants now.
Browse Colorectal Neoplasms studies →21 of the 206 studies testing oxaliplatin in Colorectal Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
Sun Yat-sen University · Sites in China
Ages 18–70
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Sites in United States
Ages 18+
AbbVie · Sites in United States, Australia, Austria and 12 more countries
Ages 18+
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · Sites in China
Ages 18–75
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Sites in China
Ages 18–70
By country, each count listing its studies:
Oxaliplatin: first FDA approval 2002 (ELOXATIN). What it is approved for, and how studies give it, is on its page →
Of the 1,178 Colorectal Neoplasms studies recruiting now, 761 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
206 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 45 · Phase 2 130 · Phase 3 40 · Phase 4 5
First in 1998; this study’s year is marked. 13 started in 2003.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 2,035 is above the median of 76 across 4,810 interventional studies indexed under Colorectal Neoplasms.
Median enrollment 50 across the 183 interventional studies. Of the 134 that completed or were terminated, 35 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 206 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 331 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
111 studies in Colorectal Neoplasms by Hoffmann-La Roche: 3 open now, 6 under way, none of them phase 3. Of 100 finished, 52 (52%) have results posted.
Among the 111 studies in Colorectal Neoplasms by Hoffmann-La Roche, this one is the 2nd largest by enrollment of the 77 interventional ones that give a count, is one of 3 that started in 2003, is one of 15 in phase 3, and was the 6th registered.
Hoffmann-La Roche’s Colorectal Neoplasms studies by the year they started, since 1998.
4 of the studies testing oxaliplatin in Colorectal Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07233850Shenyang Sunshine Pharmaceutical Co., LTD.A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal Cancers | 2026-12 |
| NCT07229846Yanqiao ZhangA Single-arm, Single-center, Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Bevacizumab and Standard Chemotherapy as First-line Treatment for MSS/pMMR Metastatic Colorectal Cancer With BRAF V600E Mutation | 2027-02 |
| NCT07570914Tianjin Medical University Cancer Institute and HospitalHepatic Arterial Infusion of Liposomal Irinotecan Plus Oxaliplatin and Capecitabine as Adjuvant Therapy for Colorectal Cancer Liver Metastases | 2027-05-30 |
| NCT06269978Arjun MittraIntraperitoneal Oxaliplatin and Fluorouracil for the Treatment of Patients With Peritoneal Metastases From Colorectal Cancer | 2027-09-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 206 studies testing oxaliplatin in Colorectal Neoplasms, from their registry updates:
Among Hoffmann-La Roche’s 111 in Colorectal Neoplasms:
This tab as a report to print or save as PDF → With an account.
This 4 arm study assessed the efficacy and safety of oral capecitabine (Xeloda) or intravenous (iv) fluorouracil/leucovorin, in combination with iv oxaliplatin (Eloxatin) with or without iv bevacizumab (Avastin), as a first-line treatment in patients with metastatic colorectal cancer. Patients were randomized to receive 1) XELOX (Xeloda 1000 mg/m\^2 orally [po] twice a day [bid] on Days 1-15 + oxaliplatin in 3 week cycles), 2) FOLFOX-4 (oxaliplatin + leucovorin + fluorouracil [5-FU] in 2 week cycles), 3) XELOX + bevacizumab (7.5 mg iv on Day 1 in 3 week cycles), or 4) FOLFOX-4 + bevacizumab (5 mg iv on Day 1 in 2 week cycles).
This study was conducted in 2 parts: An initial 2-arm part in which patients were randomized to 1 of 2 different treatment groups (XELOX or FOLFOX-4), and a subsequent 2 x 2 factorial part, added to the study through a protocol amendment, in which additional patients were randomized into one of 4 different treatment groups (XELOX + placebo, FOLFOX-4 + placebo, XELOX + bevacizumab, or FOLFOX-4 + bevacizumab). Due to the comparison of the oral agent capecitabine with bolus and infused fluorouracil, the study was not blinded with respect to these 2 treatments. The study was double-blind with regard to the administration of bevacizumab, ie, there was a placebo control for bevacizumab in the second part of the study.
The study consisted of 3 phases, a Primary Study Treatment Phase, a Post-Study Treatment Phase, and a Follow-Up Phase.
Primary Study Treatment Phase
Patients were to receive up to 16 cycles (2-arm part of the study) or 24 cycles (4-arm part of the study) of treatment during the Primary Study Treatment Phase (48 weeks).
Post-Study Treatment Phase
Patients who completed the 48-week primary study treatment phase without progressive disease were eligible to enter the post-study treatment phase at the discretion of the investigator and the sponsor. Patients who entered this phase were to continue treatment on the same regimen to which they were initially randomized until either progression of disease was documented, unacceptable toxicity occurred, or the patient withdrew consent.
Follow-up Phase
Patients who terminated study treatment during the primary or post-study treatment phase were followed until disease progression or death.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients in the 2-arm part of the study received oxaliplatin 130 mg/m\^2 intravenously (iv) on Day 1 of every 3 week cycle + capecitabine 1000 mg/m\^2 orally twice a day for the first 2 weeks of every 3 week cycle. Patients in the 4-arm part of the study received the same treatments plus placebo for bevacizumab 7.5 mg/kg iv on Day 1 of every 3 week cycle.
Drug: Oxaliplatin 130 mg/m^2 · Drug: Capecitabine 1000 mg/m^2 · Drug: Placebo for bevacizumab 7.5 mg/kg
Patients in the 4-arm part of the study received oxaliplatin 130 mg/m\^2 intravenously (iv) on Day 1 of every 3 week cycle + capecitabine 1000 mg/m\^2 orally twice a day for the first 2 weeks of every 3 week cycle + bevacizumab 7.5 mg/kg iv on Day 1 of every 3 week cycle.
Drug: Oxaliplatin 130 mg/m^2 · Drug: Capecitabine 1000 mg/m^2 · Drug: Bevacizumab 7.5 mg/kg
Patients in the 2-arm part of the study received oxaliplatin 85 mg/m\^2 intravenously (iv) + leucovorin 200 mg/m\^2 iv on Day 1 of every 2 week cycle + fluorouracil 400 mg/m\^2 bolus injection over 2 to 4 min followed by 600 mg/m\^2 continuous infusion over 22 h on Days 1 and 2 of every 2 week cycle. Patients in the 4-arm part of the study received the same treatments plus placebo for bevacizumab 5 mg/kg iv on Day 1 of every 2 week cycle.
Drug: Oxaliplatin 85 mg/m^2 · Drug: Leucovorin 200 mg/m^2 · Drug: Fluorouracil 400 mg/m^2 · Drug: Placebo for bevacizumab 5 mg/kg
Patients in the 4-arm part of the study received oxaliplatin 85 mg/m\^2 intravenously (iv) + leucovorin 200 mg/m\^2 iv + bevacizumab 5 mg/kg iv on Day 1 of every 2 week cycle + fluorouracil 400 mg/m\^2 bolus injection over 2 to 4 min followed by 600 mg/m\^2 continuous infusion over 22 h on Days 1 and 2 of every 2 week cycle.
Drug: Oxaliplatin 85 mg/m^2 · Drug: Leucovorin 200 mg/m^2 · Drug: Fluorouracil 400 mg/m^2 · Drug: Bevacizumab 5 mg/kg
Drug page: Oxaliplatin
Oxaliplatin was administered in a 2 h infusion before the first dose of capecitabine.
Also known as: Eloxatin
Drug page: Capecitabine
Capecitabine was taken within 30 min after the end of breakfast and dinner.
Also known as: Xeloda
Drug page: Bevacizumab
Bevacizumab was administered in a 30 to 90 min infusion.
Also known as: Avastin
Placebo control for bevacizumab (volume equivalent to 7.5 mg/kg bevacizumab) was administered in a 30 to 90 min infusion.
Drug page: Oxaliplatin
Oxaliplatin 85 mg/m\^2 was administered simultaneously with leucovorin in a 2 h infusion.
Also known as: Eloxatin
Drug page: Leucovorin
Leucovorin was administered simultaneously with oxaliplatin 85 mg/m\^2 in a 2 h infusion.
Drug page: Fluorouracil
Also known as: Efudex
Drug page: Bevacizumab
Bevacizumab was administered in a 30 to 90 min infusion.
Also known as: Avastin
Placebo control for bevacizumab (volume equivalent to 5 mg/kg bevacizumab) was administered in a 30 to 90 min infusion.
Progression-free Survival (PFS) as Assessed by the Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST) by General Approach (Participants With Curative Surgery Censored): Non-inferiority of XELOX Versus FOLFOX-4
PFS was defined as the time from randomization to progressive disease or death. Participants with neither disease progression nor death were censored at the last date of the last tumor assessment that confirmed that their disease had not progressed. Participants with no tumor assessments after baseline who were alive at the time of clinical cutoff were censored at the date of randomization. Participants who underwent surgical resection with curative intent without prior progression were censored at the date of surgery. PFS was based on tumor assessments made by the investigators according to the RECIST criteria. Non-inferiority analysis that followed the general approach took into account all tumor assessments obtained during the primary study treatment phase, the post-study treatment phase and those obtained during the follow-up phase. Non-inferiority of the XELOX-containing arms compared with the FOLFOX-4- containing arms was investigated.
Time frame: Baseline until disease progression or death, approximately 2 years 6 months
PFS as Assessed by the Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST) by General Approach (Participants With Curative Surgery Censored) - Superiority of Chemotherapy Plus BV Over Chemotherapy Alone
PFS was defined as the time from randomization to progressive disease or death. Participants with neither disease progression nor death were censored at the last date of the last tumor assessment that confirmed that their disease had not progressed. Participants with no tumor assessments after baseline who were alive at the time of clinical cutoff were censored at the date of randomization. Participants who underwent surgical resection with curative intent without prior progression were censored at the date of surgery. PFS was based on tumor assessments made by the investigators according to the RECIST criteria. Superiority analysis that followed the general approach took into account all tumor assessments obtained during the primary study treatment phase, the post-study treatment phase and those obtained during the follow-up phase. Superiority of the BV-containing arms was compared with the chemotherapy alone arms.
Time frame: Baseline until disease progression or death, approximately 2 years 6 months
PFS as Assessed by the Independent Review Committee (IRC) (General Approach, Participants With Curative Surgery Censored) - Non-inferiority of XELOX Versus FOLFOX-4
PFS is defined as the time from randomization to disease progression (PD) or death due to any cause. Participants with neither disease progression nor death were censored at the last date of the last tumor assessment that confirmed that their disease had not progressed. Participants who underwent surgical resection with curative intent without prior progression were censored at the date of surgery. PFS was analyzed on the basis of the tumor response assessments made by the IRC. Non-inferiority analysis that followed the general approach took into account all tumor assessments obtained during the primary study treatment phase, the post-study treatment phase and those obtained during the follow-up phase. Non-inferiority of the XELOX-containing arms was compared with the FOLFOX-4-containing arms.
Time frame: Baseline until disease progression or death, approximately 2 years 6 months
PFS as Assessed by the Independent Review Committee (IRC) (General Approach, Participants With Curative Surgery Censored) - Superiority of Chemotherapy Plus BV Over Chemotherapy Alone
PFS is defined as the time from randomization to disease progression (PD) or death due to any cause. Participants with neither disease progression nor death were censored at the last date of the last tumor assessment that confirmed that their disease had not progressed. Participants who underwent surgical resection with curative intent without prior progression were censored at the date of surgery. PFS was analyzed on the basis of the tumor response assessments made by the IRC. Superiority analysis that followed the general approach took into account all tumor assessments obtained during the primary study treatment phase, the post-study treatment phase and those obtained during the follow-up phase. Superiority of the bevacizumab-containing arms was compared with the placebo-containing arms.
Time frame: Baseline until disease progression or death, approximately 2 years 6 months
PFS (On-treatment Approach): Non-inferiority of XELOX Versus FOLFOX-4
PFS is defined as the time from randomization to disease progression (PD) or death due to any cause. The on-treatment analysis included only tumor assessments and death events that occurred no later than 28 days after the last confirmed intake of any study medication in the primary study treatment phase. Participants who did not have an event during this interval were censored at the date of the last tumor assessment within this time window, or on day 1 if no tumor assessment was available after baseline. Participants who underwent surgical resection with curative intent without prior progression within 28 days after the last confirmed intake of any study medication in the primary study treatment phase were censored at the date of surgery. The on-treatment approach excluded the possible impact of other treatments that might have been started before disease progression. Non-inferiority of the XELOX-containing arms was compared with the FOLFOX-4-containing arms.
Time frame: Baseline until disease progression or death, approximately 2 years 6 months
PFS (On-treatment Approach): Superiority of Chemotherapy Plus BV Over Chemotherapy Alone
PFS is defined as the time from randomization to disease progression (PD) or death due to any cause. The on-treatment analysis included only tumor assessments and death events that occurred no later than 28 days after the last confirmed intake of any study medication in the primary study treatment phase. Participants who did not have an event during this interval were censored at the date of the last tumor assessment within this time window, or on day 1 if no tumor assessment was available after baseline. Participants who underwent surgical resection with curative intent without prior progression within 28 days after the last confirmed intake of any study medication in the primary study treatment phase were censored at the date of surgery. The on-treatment approach excluded the possible impact of other treatments that might have been started before disease progression. Non-inferiority of the XELOX-containing arms was compared with the FOLFOX-4-containing arms.
Time frame: Baseline until disease progression or death, approximately 2 years 6 months
PFS by General Approach, Participants With Curative Surgery Not Censored: Non-inferiority of XELOX Versus FOLFOX-4
PFS is defined as the time from randomization to disease progression (PD) or death due to any cause. Participants who underwent curative surgery after experiencing a sufficient shrinkage of their tumor were not censored at the date of surgery, but any relapse, new occurrence of colorectal cancer, or death was considered as an event. Non-inferiority analysis that followed the general approach took into account all tumor assessments obtained during the primary study treatment phase, the post-study treatment phase and those obtained during the follow-up phase. Non-inferiority of the XELOX-containing arms was compared with the FOLFOX-4-containing arms.
Time frame: Baseline until disease progression or death, approximately 2 years 6 months
PFS by General Approach, Participants With Curative Surgery Not Censored: Superiority of Chemotherapy Plus BV Over Chemotherapy Alone
PFS is defined as the time from randomization to disease progression (PD) or death due to any cause. Participants who underwent curative surgery after experiencing a sufficient shrinkage of their tumor were not censored at the date of surgery, but any relapse, new occurrence of colorectal cancer, or death was considered as an event. Superiority analysis that followed the general approach took into account all tumor assessments obtained during the primary study treatment phase, the post-study treatment phase and those obtained during the follow-up phase. Superiority of the BV-containing arms was compared with the chemotherapy alone arms.
Time frame: Baseline until disease progression or death, approximately 2 years 6 months
Overall Survival: Non-inferiority of XELOX Versus FOLFOX-4
Overall survival was defined as the time from the date of randomization to the date of death. Participants who were not reported to have died at the time of the clinical cut-off date for the analysis were censored using the date they were last known to be alive. Non-inferiority of the XELOX-containing arms was compared with the FOLFOX-4-containing arms.
Time frame: Baseline until disease progression or death, approximately 2 years 6 months
Overall Survival: Superiority of Chemotherapy Plus BV Over Chemotherapy Alone
Overall survival was defined as the time from the date of randomization to the date of death. Participants who were not reported to have died at the time of the clinical cut-off date for the analysis were censored using the date they were last known to be alive. Superiority of the BV-containing arms was compared with the chemotherapy alone arms.
Time frame: Baseline until disease progression or death, approximately 2 years 6 months
Best Overall Response (BOR) as Assessed by the Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST): Non-inferiority of XELOX Versus FOLFOX-4
According to the RECIST criteria, BOR in an individual participant was defined as the best response recorded from the start of the treatment until disease progression or recurrence. Only tumor assessments as assessed by the investigator and made up to and including 28 days after last intake of study medication in the primary study treatment phase not later than date of first curative surgery were included in these analyses. Responders were defined as the percentage of participants with a confirmed best overall response of complete response (CR) or partial response (PR). Non-inferiority of the XELOX-containing arms was compared with the FOLFOX-4-containing arms.
Time frame: From baseline until disease progression/recurrence, approximately 2 years 6 months
Best Overall Response (BOR) as Assessed by the Investigator According to RECIST: Superiority of Chemotherapy Plus BV Over Chemotherapy Alone
According to the RECIST criteria, BOR in an individual participant was defined as the best response recorded from the start of the treatment until disease progression or recurrence. Only tumor assessments as assessed by the investigator and made up to and including 28 days after last intake of study medication in the primary study treatment phase not later than date of first curative surgery were included in these analyses. Responders were defined as the percentage of participants with a confirmed best overall response of complete response (CR) or partial response (PR). Superiority of the BV-containing arms was compared with the chemotherapy alone arms.
Time frame: From baseline until disease progression/recurrence, approximately 2 years 6 months
BOR as Assessed by the IRC According to RECIST: Non-inferiority of XELOX Versus FOLFOX-4
According to the RECIST criteria, the BOR in an individual participant was the best response recorded from the start of the treatment until disease progression/recurrence (taking the smallest measurements recorded since the baseline assessment as a reference for PD). The BOR as assessed by the IRC was determined based on tumor assessments that were made up to and including 28 days after last intake of study medication in the primary study treatment phase. Responders were defined as the percentage of participants with a complete response (CR) or partial response (PR). Non-inferiority of the XELOX-containing arms was compared with the FOLFOX-4-containing arms.
Time frame: From baseline until disease progression/recurrence, approximately 2 years 6 months
BOR as Assessed by the IRC According to RECIST: Superiority of Chemotherapy Plus BV Over Chemotherapy Alone
According to the RECIST criteria, the BOR in an individual participant was the best response recorded from the start of the treatment until disease progression/recurrence (taking the smallest measurements recorded since the baseline assessment as a reference for PD). The BOR as assessed by the IRC was determined based on tumor assessments that were made up to and including 28 days after last intake of study medication in the primary study treatment phase. Responders were defined as the percentage of participants with a complete response (CR) or partial response (PR). Superiority of the BV-containing arms was compared with the chemotherapy alone arms.
Time frame: From baseline until disease progression/recurrence, approximately 2 years 6 months
Time to Treatment Failure (TTF) as Assessed by the Investigator According to RECIST: Non-inferiority of XELOX Versus FOLFOX-4
Time to treatment failure was defined as the time from the date of randomization to the date of discontinuation of the primary study treatment phase due to adverse event/intercurrent illness, insufficient therapeutic response, death, failure to return, refusing treatment/being unwilling to cooperate, or withdrawing consent; discontinuation of the post study treatment phase due to adverse event, progressive disease, death, participant refusal/administrative reasons, or withdrawing consent; documented disease progression; or death due to any cause, whichever occurred first. The general approach took into account all tumor assessments obtained during the primary study treatment phase, the post-study treatment phase and those obtained during the follow-up phase.The on-treatment approach included only tumor assessments and deaths that occurred no later than 28 days after the last confirmed intake of any study medication in the primary study treatment phase only.
Time frame: From baseline until disease progression/recurrence, approximately 2 years 6 months
Time to Treatment Failure as Assessed by the Investigator According to RECIST: Superiority of Chemotherapy Plus BV Over Chemotherapy Alone
Time to treatment failure was defined as the time from the date of randomization to the date of discontinuation of the primary study treatment phase due to adverse event/intercurrent illness, insufficient therapeutic response, death, failure to return, refusing treatment/being unwilling to cooperate, or withdrawing consent; discontinuation of the post study treatment phase due to adverse event, progressive disease, death, participant refusal/administrative reasons, or withdrawing consent; documented disease progression; or death due to any cause, whichever occurred first. The general approach included all tumor assessments or deaths that occurred during the primary study treatment phase, the post-study treatment phase, or the follow-up phase. The on-treatment approach included only tumor assessments and deaths that occurred no later than 28 days after the last confirmed intake of any study medication in the primary study treatment phase only.
Time frame: From baseline until disease progression/recurrence, approximately 2 years 6 months
Time to Response as Assessed by the Investigator According to RECIST: Non-inferiority of XELOX Versus FOLFOX-4
For participants whose BOR was CR or PR, time to response was measured as the time from randomization to the first time when the measurement criteria for CR or PR (whichever status was recorded first) was met. It was based on tumor assessments made by the investigators according to the RECIST criteria. Results were reported as the number of participants achieving a response in 8 time categories from Week 1 to Week 54. Non-inferiority of the XELOX-containing arms was compared with the FOLFOX-4-containing arms.
Time frame: Week 1 to Week 54
Time to Response as Assessed by the Investigator According to RECIST: Superiority of Chemotherapy Plus BV Over Chemotherapy Alone
For participants whose BOR was CR or PR, time to response was measured as the time from randomization to the first time when the measurement criteria for CR or PR (whichever status was recorded first) was met. It was based on tumor assessments made by the investigators according to the RECIST criteria. Results were reported as the number of participants achieving a response in 8 time categories from Week 1 to Week 54. Superiority of the BV-containing arms was compared with the chemotherapy alone arms.
Time frame: Week 1 to Week 54
Duration of Overall Response as Assessed by the Investigator According to RECIST: Non-inferiority of XELOX Versus FOLFOX-4
Duration of overall response was measured from the time that measurement criteria were first met for CR or PR (whichever status was recorded first) until the first date when progressive disease or death was documented. It was based on tumor assessments made by the investigators according to the RECIST criteria. Participants who neither progressed nor died were censored at the date of the last tumor assessment. Participants undergoing surgical resection with curative intent were censored at the date of surgery. Non-inferiority of the XELOX-containing arms was compared with the FOLFOX-4-containing arms.
Time frame: From baseline until disease progression/recurrence, approximately 2 years 6 months
Duration of Overall Response as Assessed by the Investigator According to RECIST: Superiority Analysis of Chemotherapy Plus Bevacizumab Versus Chemotherapy Alone
Duration of overall response was measured from the time that measurement criteria were first met for CR or PR (whichever status was recorded first) until the first date when progressive disease or death was documented. It was based on tumor assessments made by the investigators according to the RECIST criteria. Participants who neither progressed nor died were censored at the date of the last tumor assessment. Participants undergoing surgical resection with curative intent were censored at the date of surgery. Superiority of the BV-containing arms was compared with the chemotherapy alone arms.
Time frame: From baseline until disease progression/recurrence, approximately 2 years 6 months
Duration of Complete Response as Assessed by the Investigator According to RECIST: Non-inferiority of XELOX Versus FOLFOX-4
For complete responders, the duration of complete response was measured from the time measurement criteria were first met for complete response until the date that progressive disease (or death) was documented. Non-inferiority of the XELOX-containing arms was compared with the FOLFOX-4-containing arms.
Time frame: From baseline until disease progression/recurrence, approximately 2 years 6 months
Duration of Complete Response as Assessed by the Investigator According to RECIST: Superiority of Chemotherapy Plus BV Over Chemotherapy Alone
For complete responders, the duration of complete response was measured from the time measurement criteria were first met for complete response until the date that progressive disease (or death) was documented. Superiority of the BV-containing arms was compared with the chemotherapy alone arms.
Time frame: From baseline until disease progression/recurrence, approximately 2 years 6 months
This study was conducted in 32 countries - Australia, Austria, Brazil, Canada, China, Czech Republic, Denmark, Finland, France, Germany, Great Britain, Guatemala, Hong Kong, Hungary, Ireland, Israel, Italy, Korea, Mexico, New Zealand, Norway, Panama, Portugal, Russia, South Africa, Spain, Sweden, Switzerland, Taiwan, Thailand, Turkey and USA.
| Milestone | Xelox | Folfox-4 | Xelox+P | Folfox-4+P | Xelox+BV | Folfox-4+BV |
|---|---|---|---|---|---|---|
| Started | 317 | 317 | 350 | 351 | 350 | 349 |
| Completed | 22 | 15 | 36 | 31 | 48 | 48 |
| Not completed | 295 | 302 | 314 | 320 | 302 | 301 |
| Withdrew: Ongoing | 0 | 0 | 5 | 7 | 7 | 4 |
| Withdrew: Admin/other | 29 | 38 | 31 | 45 | 48 | 42 |
| Withdrew: Adverse event | 99 | 92 | 71 | 72 | 109 | 101 |
| Withdrew: Death | 14 | 8 | 2 | 5 | 8 | 8 |
| Withdrew: Failure to return | 5 | 5 | 0 | 0 | 0 | 2 |
| Withdrew: Insufficient therapeutic response | 131 | 127 | 175 | 154 | 101 | 102 |
| Withdrew: Refused treatment | 15 | 26 | 17 | 31 | 24 | 27 |
| Withdrew: Withdrew | 2 | 3 | 8 | 2 | 4 | 9 |
| Withdrew: Other violation | 0 | 1 | 1 | 1 | 0 | 1 |
| Withdrew: Violation criteria | 0 | 2 | 4 | 3 | 1 | 5 |
| Milestone | Xelox | Folfox-4 | Xelox+P | Folfox-4+P | Xelox+BV | Folfox-4+BV |
|---|---|---|---|---|---|---|
| Started | 8 | 13 | 21 | 17 | 36 | 29 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 8 | 13 | 21 | 17 | 36 | 29 |
| Withdrew: Missing reason | 1 | 3 | 12 | 8 | 18 | 17 |
| Withdrew: Adverse event | 2 | 3 | 1 | 0 | 5 | 1 |
| Withdrew: Eligible for surgery | 2 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Insufficient therapeutic response | 1 | 4 | 5 | 6 | 7 | 9 |
| Withdrew: Participant refusal/admin reasons | 1 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Participant had complete response | 1 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: More than 21 days delay between cycles | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Investigator decision (enough treatment) | 0 | 1 | 1 | 0 | 1 | 0 |
| Withdrew: Participant withdrew consent | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Participant will start new treatment | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Participant wanted break from treatment | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Participant completed treatment | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Surgery | 0 | 0 | 0 | 1 | 1 | 0 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Participant had progressive disease | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Participant/physician decision to stop | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Preplanned 6 cycles after surgery | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Investigator decision | 0 | 0 | 0 | 0 | 0 | 1 |
| Milestone | Xelox | Folfox-4 | Xelox+P | Folfox-4+P | Xelox+BV | Folfox-4+BV |
|---|---|---|---|---|---|---|
| Started | 284 | 299 | 298 | 299 | 278 | 272 |
| Completed | 110 | 93 | 178 | 187 | 186 | 171 |
| Not completed | 174 | 206 | 120 | 112 | 92 | 101 |
| Withdrew: Death | 174 | 206 | 120 | 112 | 92 | 101 |
PFS was defined as the time from randomization to progressive disease or death. Participants with neither disease progression nor death were censored at the last date of the last tumor assessment that confirmed that their disease had not progressed. Participants with no tumor assessments after baseline who were alive at the time of clinical cutoff were censored at the date of randomization. Participants who underwent surgical resection with curative intent without prior progression were censored at the date of surgery. PFS was based on tumor assessments made by the investigators according to the RECIST criteria. Non-inferiority analysis that followed the general approach took into account all tumor assessments obtained during the primary study treatment phase, the post-study treatment phase and those obtained during the follow-up phase. Non-inferiority of the XELOX-containing arms compared with the FOLFOX-4- containing arms was investigated.
| days | FOLFOX-4/FOLFOX-4+P/FOLFOX-4+BV | XELOX/XELOX+P/XELOX+BV |
|---|---|---|
| Progression-free Survival (PFS) as Assessed by the Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST) by General Approach (Participants With Curative Surgery Censored): Non-inferiority of XELOX Versus FOLFOX-4 | 259 (245 to 268) | 241 (229 to 254) |
PFS is defined as the time from randomization to disease progression (PD) or death due to any cause. Participants with neither disease progression nor death were censored at the last date of the last tumor assessment that confirmed that their disease had not progressed. Participants who underwent surgical resection with curative intent without prior progression were censored at the date of surgery. PFS was analyzed on the basis of the tumor response assessments made by the IRC. Non-inferiority analysis that followed the general approach took into account all tumor assessments obtained during the primary study treatment phase, the post-study treatment phase and those obtained during the follow-up phase. Non-inferiority of the XELOX-containing arms was compared with the FOLFOX-4-containing arms.
| days | FOLFOX-4/FOLFOX-4+P/FOLFOX-4+BV | XELOX/XELOX+P/XELOX+BV |
|---|---|---|
| PFS as Assessed by the Independent Review Committee (IRC) (General Approach, Participants With Curative Surgery Censored) - Non-inferiority of XELOX Versus FOLFOX-4 | 304.0 (281 to 319) | 261.0 (246 to 276) |
PFS is defined as the time from randomization to disease progression (PD) or death due to any cause. Participants with neither disease progression nor death were censored at the last date of the last tumor assessment that confirmed that their disease had not progressed. Participants who underwent surgical resection with curative intent without prior progression were censored at the date of surgery. PFS was analyzed on the basis of the tumor response assessments made by the IRC. Superiority analysis that followed the general approach took into account all tumor assessments obtained during the primary study treatment phase, the post-study treatment phase and those obtained during the follow-up phase. Superiority of the bevacizumab-containing arms was compared with the placebo-containing arms.
| days | FOLFOX-4+P/XELOX+P | FOLFOX-4+BV/XELOX+BV |
|---|---|---|
| PFS as Assessed by the Independent Review Committee (IRC) (General Approach, Participants With Curative Surgery Censored) - Superiority of Chemotherapy Plus BV Over Chemotherapy Alone | 259.0 (244 to 278) | 335.0 (310 to 363) |
PFS is defined as the time from randomization to disease progression (PD) or death due to any cause. The on-treatment analysis included only tumor assessments and death events that occurred no later than 28 days after the last confirmed intake of any study medication in the primary study treatment phase. Participants who did not have an event during this interval were censored at the date of the last tumor assessment within this time window, or on day 1 if no tumor assessment was available after baseline. Participants who underwent surgical resection with curative intent without prior progression within 28 days after the last confirmed intake of any study medication in the primary study treatment phase were censored at the date of surgery. The on-treatment approach excluded the possible impact of other treatments that might have been started before disease progression. Non-inferiority of the XELOX-containing arms was compared with the FOLFOX-4-containing arms.
| days | FOLFOX-4/FOLFOX-4+P/FOLFOX-4+BV | XELOX/XELOX+P/XELOX+BV |
|---|---|---|
| PFS (On-treatment Approach): Non-inferiority of XELOX Versus FOLFOX-4 | 268.0 (252 to 290) | 234.0 (221 to 251) |
PFS is defined as the time from randomization to disease progression (PD) or death due to any cause. The on-treatment analysis included only tumor assessments and death events that occurred no later than 28 days after the last confirmed intake of any study medication in the primary study treatment phase. Participants who did not have an event during this interval were censored at the date of the last tumor assessment within this time window, or on day 1 if no tumor assessment was available after baseline. Participants who underwent surgical resection with curative intent without prior progression within 28 days after the last confirmed intake of any study medication in the primary study treatment phase were censored at the date of surgery. The on-treatment approach excluded the possible impact of other treatments that might have been started before disease progression. Non-inferiority of the XELOX-containing arms was compared with the FOLFOX-4-containing arms.
| days | FOLFOX-4+P/XELOX+P | FOLFOX-4+BV/XELOX+BV |
|---|---|---|
| PFS (On-treatment Approach): Superiority of Chemotherapy Plus BV Over Chemotherapy Alone | 241.0 (227 to 254) | 316.0 (294 to 338) |
PFS is defined as the time from randomization to disease progression (PD) or death due to any cause. Participants who underwent curative surgery after experiencing a sufficient shrinkage of their tumor were not censored at the date of surgery, but any relapse, new occurrence of colorectal cancer, or death was considered as an event. Non-inferiority analysis that followed the general approach took into account all tumor assessments obtained during the primary study treatment phase, the post-study treatment phase and those obtained during the follow-up phase. Non-inferiority of the XELOX-containing arms was compared with the FOLFOX-4-containing arms.
| days | FOLFOX-4/FOLFOX-4+P/FOLFOX-4+BV | XELOX/XELOX+P/XELOX+BV |
|---|---|---|
| PFS by General Approach, Participants With Curative Surgery Not Censored: Non-inferiority of XELOX Versus FOLFOX-4 | 260.0 (247 to 270) | 244.0 (230 to 255) |
PFS is defined as the time from randomization to disease progression (PD) or death due to any cause. Participants who underwent curative surgery after experiencing a sufficient shrinkage of their tumor were not censored at the date of surgery, but any relapse, new occurrence of colorectal cancer, or death was considered as an event. Superiority analysis that followed the general approach took into account all tumor assessments obtained during the primary study treatment phase, the post-study treatment phase and those obtained during the follow-up phase. Superiority of the BV-containing arms was compared with the chemotherapy alone arms.
| days | FOLFOX-4+P/XELOX+P | FOLFOX-4+BV/XELOX+BV |
|---|---|---|
| PFS by General Approach, Participants With Curative Surgery Not Censored: Superiority of Chemotherapy Plus BV Over Chemotherapy Alone | 245.0 (230 to 258) | 287.0 (276 to 300) |
Overall survival was defined as the time from the date of randomization to the date of death. Participants who were not reported to have died at the time of the clinical cut-off date for the analysis were censored using the date they were last known to be alive. Non-inferiority of the XELOX-containing arms was compared with the FOLFOX-4-containing arms.
| days | FOLFOX-4/FOLFOX-4+P/FOLFOX-4+BV | XELOX/XELOX+P/XELOX+BV |
|---|---|---|
| Overall Survival: Non-inferiority of XELOX Versus FOLFOX-4 | 549.0 (528 to 576) | 577.0 (535 to 615) |
Overall survival was defined as the time from the date of randomization to the date of death. Participants who were not reported to have died at the time of the clinical cut-off date for the analysis were censored using the date they were last known to be alive. Superiority of the BV-containing arms was compared with the chemotherapy alone arms.
| days | FOLFOX-4+P/XELOX+P | FOLFOX-4+BV/XELOX+BV |
|---|---|---|
| Overall Survival: Superiority of Chemotherapy Plus BV Over Chemotherapy Alone | 574.0 (537 to 592) | 551.0 (528 to 635) |
PFS was defined as the time from randomization to progressive disease or death. Participants with neither disease progression nor death were censored at the last date of the last tumor assessment that confirmed that their disease had not progressed. Participants with no tumor assessments after baseline who were alive at the time of clinical cutoff were censored at the date of randomization. Participants who underwent surgical resection with curative intent without prior progression were censored at the date of surgery. PFS was based on tumor assessments made by the investigators according to the RECIST criteria. Superiority analysis that followed the general approach took into account all tumor assessments obtained during the primary study treatment phase, the post-study treatment phase and those obtained during the follow-up phase. Superiority of the BV-containing arms was compared with the chemotherapy alone arms.
| days | FOLFOX-4+P/XELOX+P | FOLFOX-4+BV/XELOX+BV |
|---|---|---|
| PFS as Assessed by the Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST) by General Approach (Participants With Curative Surgery Censored) - Superiority of Chemotherapy Plus BV Over Chemotherapy Alone | 244.0 (230 to 257) | 285.0 (271 to 297) |
According to the RECIST criteria, BOR in an individual participant was defined as the best response recorded from the start of the treatment until disease progression or recurrence. Only tumor assessments as assessed by the investigator and made up to and including 28 days after last intake of study medication in the primary study treatment phase not later than date of first curative surgery were included in these analyses. Responders were defined as the percentage of participants with a confirmed best overall response of complete response (CR) or partial response (PR). Non-inferiority of the XELOX-containing arms was compared with the FOLFOX-4-containing arms.
| Percentage of responders | FOLFOX-4/FOLFOX-4+P/FOLFOX-4+BV | XELOX/XELOX+P/XELOX+BV |
|---|---|---|
| Best Overall Response (BOR) as Assessed by the Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST): Non-inferiority of XELOX Versus FOLFOX-4 | 49.4 | 46.4 |
According to the RECIST criteria, BOR in an individual participant was defined as the best response recorded from the start of the treatment until disease progression or recurrence. Only tumor assessments as assessed by the investigator and made up to and including 28 days after last intake of study medication in the primary study treatment phase not later than date of first curative surgery were included in these analyses. Responders were defined as the percentage of participants with a confirmed best overall response of complete response (CR) or partial response (PR). Superiority of the BV-containing arms was compared with the chemotherapy alone arms.
| Percentage of responders | FOLFOX-4+P/XELOX+P | FOLFOX-4+BV/XELOX+BV |
|---|---|---|
| Best Overall Response (BOR) as Assessed by the Investigator According to RECIST: Superiority of Chemotherapy Plus BV Over Chemotherapy Alone | 49.2 | 46.5 |
According to the RECIST criteria, the BOR in an individual participant was the best response recorded from the start of the treatment until disease progression/recurrence (taking the smallest measurements recorded since the baseline assessment as a reference for PD). The BOR as assessed by the IRC was determined based on tumor assessments that were made up to and including 28 days after last intake of study medication in the primary study treatment phase. Responders were defined as the percentage of participants with a complete response (CR) or partial response (PR). Non-inferiority of the XELOX-containing arms was compared with the FOLFOX-4-containing arms.
| Percentage of responders | FOLFOX-4/FOLFOX-4+P/FOLFOX-4+BV | XELOX/XELOX+P/XELOX+BV |
|---|---|---|
| BOR as Assessed by the IRC According to RECIST: Non-inferiority of XELOX Versus FOLFOX-4 | 38.6 | 37.1 |
According to the RECIST criteria, the BOR in an individual participant was the best response recorded from the start of the treatment until disease progression/recurrence (taking the smallest measurements recorded since the baseline assessment as a reference for PD). The BOR as assessed by the IRC was determined based on tumor assessments that were made up to and including 28 days after last intake of study medication in the primary study treatment phase. Responders were defined as the percentage of participants with a complete response (CR) or partial response (PR). Superiority of the BV-containing arms was compared with the chemotherapy alone arms.
| Percentage of responders | FOLFOX-4+P/XELOX+P | FOLFOX-4+BV/XELOX+BV |
|---|---|---|
| BOR as Assessed by the IRC According to RECIST: Superiority of Chemotherapy Plus BV Over Chemotherapy Alone | 37.5 | 37.5 |
Time to treatment failure was defined as the time from the date of randomization to the date of discontinuation of the primary study treatment phase due to adverse event/intercurrent illness, insufficient therapeutic response, death, failure to return, refusing treatment/being unwilling to cooperate, or withdrawing consent; discontinuation of the post study treatment phase due to adverse event, progressive disease, death, participant refusal/administrative reasons, or withdrawing consent; documented disease progression; or death due to any cause, whichever occurred first. The general approach took into account all tumor assessments obtained during the primary study treatment phase, the post-study treatment phase and those obtained during the follow-up phase.The on-treatment approach included only tumor assessments and deaths that occurred no later than 28 days after the last confirmed intake of any study medication in the primary study treatment phase only.
| days | FOLFOX-4/FOLFOX-4+P/FOLFOX-4+BV | XELOX/XELOX+P/XELOX+BV |
|---|---|---|
| General Approach | 191.0 (183 to 202) | 179.0 (171 to 187) |
| On-treatment Approach | 190.0 (182 to 200) | 176.0 (170 to 185) |
Time to treatment failure was defined as the time from the date of randomization to the date of discontinuation of the primary study treatment phase due to adverse event/intercurrent illness, insufficient therapeutic response, death, failure to return, refusing treatment/being unwilling to cooperate, or withdrawing consent; discontinuation of the post study treatment phase due to adverse event, progressive disease, death, participant refusal/administrative reasons, or withdrawing consent; documented disease progression; or death due to any cause, whichever occurred first. The general approach included all tumor assessments or deaths that occurred during the primary study treatment phase, the post-study treatment phase, or the follow-up phase. The on-treatment approach included only tumor assessments and deaths that occurred no later than 28 days after the last confirmed intake of any study medication in the primary study treatment phase only.
| days | FOLFOX-4+P/XELOX+P | FOLFOX-4+BV/XELOX+BV |
|---|---|---|
| General Approach | 183.0 (176 to 198) | 209.0 (199 to 220) |
| On-treatment Approach | 182.0 (175 to 196) | 208.0 (198 to 220) |
For participants whose BOR was CR or PR, time to response was measured as the time from randomization to the first time when the measurement criteria for CR or PR (whichever status was recorded first) was met. It was based on tumor assessments made by the investigators according to the RECIST criteria. Results were reported as the number of participants achieving a response in 8 time categories from Week 1 to Week 54. Non-inferiority of the XELOX-containing arms was compared with the FOLFOX-4-containing arms.
| Participants | FOLFOX-4/FOLFOX-4+P/FOLFOX-4+BV | XELOX/XELOX+P/XELOX+BV |
|---|---|---|
| Week 1-6 | 67 | 93 |
| Week 7-12 | 190 | 191 |
| Week 13-18 | 155 | 110 |
| Week 19-24 | 25 | 38 |
| Week 25-30 | 14 | 13 |
| Week 31-36 | 7 | 3 |
| Week 37-42 | 3 | 1 |
| Week 49-54 | 2 | 0 |
For participants whose BOR was CR or PR, time to response was measured as the time from randomization to the first time when the measurement criteria for CR or PR (whichever status was recorded first) was met. It was based on tumor assessments made by the investigators according to the RECIST criteria. Results were reported as the number of participants achieving a response in 8 time categories from Week 1 to Week 54. Superiority of the BV-containing arms was compared with the chemotherapy alone arms.
| Participants | FOLFOX-4+P/XELOX+P | XELOX/XELOX+P/XELOX+BV |
|---|---|---|
| Week 1-6 | 58 | 48 |
| Week 7-12 | 146 | 138 |
| Week 13-18 | 105 | 87 |
| Week 19-24 | 26 | 29 |
| Week 25-30 | 7 | 12 |
| Week 31-36 | 2 | 8 |
| Week 37-42 | 1 | 2 |
| Week 49-54 | 0 | 1 |
Duration of overall response was measured from the time that measurement criteria were first met for CR or PR (whichever status was recorded first) until the first date when progressive disease or death was documented. It was based on tumor assessments made by the investigators according to the RECIST criteria. Participants who neither progressed nor died were censored at the date of the last tumor assessment. Participants undergoing surgical resection with curative intent were censored at the date of surgery. Non-inferiority of the XELOX-containing arms was compared with the FOLFOX-4-containing arms.
| days | FOLFOX-4/FOLFOX-4+P/FOLFOX-4+BV | XELOX/XELOX+P/XELOX+BV |
|---|---|---|
| Duration of Overall Response as Assessed by the Investigator According to RECIST: Non-inferiority of XELOX Versus FOLFOX-4 | 239.0 (225 to 256) | 226.0 (211 to 246) |
Duration of overall response was measured from the time that measurement criteria were first met for CR or PR (whichever status was recorded first) until the first date when progressive disease or death was documented. It was based on tumor assessments made by the investigators according to the RECIST criteria. Participants who neither progressed nor died were censored at the date of the last tumor assessment. Participants undergoing surgical resection with curative intent were censored at the date of surgery. Superiority of the BV-containing arms was compared with the chemotherapy alone arms.
| days | FOLFOX-4+P/XELOX+P | FOLFOX-4+BV/XELOX+BV |
|---|---|---|
| Duration of Overall Response as Assessed by the Investigator According to RECIST: Superiority Analysis of Chemotherapy Plus Bevacizumab Versus Chemotherapy Alone | 225.0 (217 to 240) | 257.0 (241 to 278) |
For complete responders, the duration of complete response was measured from the time measurement criteria were first met for complete response until the date that progressive disease (or death) was documented. Non-inferiority of the XELOX-containing arms was compared with the FOLFOX-4-containing arms.
| days | FOLFOX-4/FOLFOX-4+P/FOLFOX-4+BV | XELOX/XELOX+P/XELOX+BV |
|---|---|---|
| Duration of Complete Response as Assessed by the Investigator According to RECIST: Non-inferiority of XELOX Versus FOLFOX-4 | 347.0 (196 to 403) | 589.0 (270 to NA) |
For complete responders, the duration of complete response was measured from the time measurement criteria were first met for complete response until the date that progressive disease (or death) was documented. Superiority of the BV-containing arms was compared with the chemotherapy alone arms.
| days | FOLFOX-4+P/XELOX+P | FOLFOX-4+BV/XELOX+BV |
|---|---|---|
| Duration of Complete Response as Assessed by the Investigator According to RECIST: Superiority of Chemotherapy Plus BV Over Chemotherapy Alone | 403.0 (228 to NA) | 386.0 (133 to 386) |
Collected over Approximately 2 years 6 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Xelox | — | 117/316 (37%) | 310/316 (98.1%) |
| Folfox-4 | — | 120/313 (38.3%) | 310/313 (99%) |
| Xelox+P | — | 121/339 (35.7%) | 330/339 (97.3%) |
| Folfox-4+P | — | 128/336 (38.1%) | 331/336 (98.5%) |
| Xelox+BV | — | 131/353 (37.1%) | 348/353 (98.6%) |
| Folfox-4+BV | — | 146/341 (42.8%) | 335/341 (98.2%) |
| Event | Xelox | Folfox-4 | Xelox+P | Folfox-4+P | Xelox+BV | Folfox-4+BV |
|---|---|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 27/316 | 13/313 | 25/339 | 7/336 | 26/353 | 8/341 |
| PyrexiaGeneral disorders | 16/316 | 16/313 | 6/339 | 16/336 | 7/353 | 15/341 |
| VomitingGastrointestinal disorders | 7/316 | 7/313 | 16/339 | 2/336 | 14/353 | 7/341 |
| Febrile neutropeniaBlood and lymphatic system disorders | 3/316 | 14/313 | 1/339 | 15/336 | 2/353 | 14/341 |
| DehydrationMetabolism and nutrition disorders | 4/316 | 9/313 | 10/339 | 2/336 | 10/353 | 4/341 |
| NeutropeniaBlood and lymphatic system disorders | 2/316 | 9/313 | 1/339 | 6/336 | 0/353 | 5/341 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 9/316 | 3/313 | 3/339 | 5/336 | 9/353 | 8/341 |
| Intestinal obstructionGastrointestinal disorders | 4/316 | 6/313 | 6/339 | 9/336 | 4/353 | 6/341 |
| Central line infectionInfections and infestations | 1/316 | 4/313 | 1/339 | 9/336 | 0/353 | 4/341 |
| Abdominal painGastrointestinal disorders | 4/316 | 7/313 | 7/339 | 6/336 | 5/353 | 7/341 |
| Event | Xelox | Folfox-4 | Xelox+P | Folfox-4+P | Xelox+BV | Folfox-4+BV |
|---|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 194/316 | 208/313 | 209/339 | 204/336 | 230/353 | 215/341 |
| DiarrhoeaGastrointestinal disorders | 207/316 | 186/313 | 208/339 | 197/336 | 210/353 | 218/341 |
| NeutropeniaBlood and lymphatic system disorders | 88/316 | 172/313 | 90/339 | 198/336 | 70/353 | 187/341 |
| FatigueGeneral disorders | 132/316 | 152/313 | 118/339 | 140/336 | 133/353 | 135/341 |
| VomitingGastrointestinal disorders | 136/316 | 123/313 | 134/339 | 127/336 | 160/353 | 127/341 |
| Stomatitis AllGastrointestinal disorders | 63/316 | 111/313 | 76/339 | 130/336 | 101/353 | 141/341 |
| ParaesthesiaNervous system disorders | 116/316 | 117/313 | 126/339 | 127/336 | 133/353 | 135/341 |
| Palmar-Plantar Erythrodysaesthesia SyndromeSkin and subcutaneous tissue disorders | 95/316 | 30/313 | 103/339 | 36/336 | 138/353 | 46/341 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 22/316 | 41/313 | 24/339 | 62/336 | 38/353 | 107/341 |
| AnorexiaMetabolism and nutrition disorders | 95/316 | 93/313 | 84/339 | 86/336 | 109/353 | 96/341 |
Baseline characteristics were described for the Intent-to-treat (ITT) population.This population included all randomized participants who provided written informed consent.
| Age, Continuous(years) | Xelox | Folfox-4 | Xelox+P | Folfox-4+P | Xelox+BV | Folfox-4+BV | Total |
|---|---|---|---|---|---|---|---|
| Mean | 60.3 ± 10.76 | 60.6 ± 10.94 | 59.1 ± 12.14 | 58.8 ± 10.87 | 59.7 ± 11.28 | 59.7 ± 10.74 | 59.7 ± 11.14 |
| Sex: Female, Male(Participants) | Xelox | Folfox-4 | Xelox+P | Folfox-4+P | Xelox+BV | Folfox-4+BV | Total |
|---|---|---|---|---|---|---|---|
| Female | 123 | 113 | 145 | 165 | 137 | 144 | 827 |
| Male | 194 | 204 | 205 | 186 | 213 | 205 | 1207 |
Showing the first 100 of 236 sites across 33 countries. Choose a country and city above to see the rest.
The record gives a start of Jul 2003, a primary completion of Jan 2006 and a completion of Apr 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2016, 10 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Oxaliplatin · Capecitabine · Bevacizumab